• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用比美吉珠单抗治疗的银屑病患者出现的具有挑战性的病例：生物治疗前真菌学筛查的作用。

Challenging case of and in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies.

作者信息

Cosio Terenzio, Shumak Ruslana Gaeta, Borselli Cristiana, Artosi Fabio, Gaziano Roberta, Campione Elena

机构信息

Department of Experimental Medicine, University of Rome "Tor Vergata", 00133, Rome, Italy.

DYNAMYC UR 7380, Faculté de Santé, Université Paris-Est Créteil (UPEC), 94010, Créteil, France.

出版信息

Med Mycol Case Rep. 2024 Nov 16;46:100683. doi: 10.1016/j.mmcr.2024.100683. eCollection 2024 Dec.

DOI:10.1016/j.mmcr.2024.100683
PMID:39634792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11616602/
Abstract

Psoriasis is a multifactorial immune-mediated disorder linked to the interleukin (IL)-17 signalling pathway. We present an unusual case of and caused by that developed after starting the IL-17A/F inhibitor bimekizumab. Our case underlines how psoriatic patients, treated with IL-17 inhibitors, should be screened for cutaneous fungal infections before and during treatment, in order to exclude a concomitant infection or the risk of its exacerbation.

摘要

银屑病是一种与白细胞介素（IL）-17信号通路相关的多因素免疫介导性疾病。我们报告了一例在开始使用IL-17A/F抑制剂比美吉珠单抗后发生的由[具体病因未给出]引起的[具体病情未给出]的不寻常病例。我们的病例强调，接受IL-17抑制剂治疗的银屑病患者在治疗前和治疗期间应进行皮肤真菌感染筛查，以排除合并感染或其加重的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/0d6ac1bc931d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/4595b141a310/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/c09ba26206b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/0d6ac1bc931d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/4595b141a310/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/c09ba26206b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffa/11616602/0d6ac1bc931d/gr3.jpg

相似文献

1
Challenging case of and in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies.使用比美吉珠单抗治疗的银屑病患者出现的具有挑战性的病例：生物治疗前真菌学筛查的作用。
Med Mycol Case Rep. 2024 Nov 16;46:100683. doi: 10.1016/j.mmcr.2024.100683. eCollection 2024 Dec.
2
Emergence of Trichophyton tonsurans-A Retrospective Multicentre Study of the Dermatophyte Spectrum in Germany.须癣毛癣菌的出现——德国皮肤癣菌谱的回顾性多中心研究
Mycoses. 2025 Apr;68(4):e70053. doi: 10.1111/myc.70053.
3
Chronically recurrent and disseminated tinea faciei/corporis--autoinoculation from asymptomatic tinea capitis carriage.慢性复发性播散性面部/体癣——源自无症状头癣携带者的自体接种。
Pediatr Dermatol. 2010 Sep-Oct;27(5):527-8. doi: 10.1111/j.1525-1470.2010.01270.x. Epub 2010 Aug 26.
4
Tinea capitis caused by Trichophyton tonsurans among adults: Clinical characteristics and treatment response.须癣毛癣菌引起的成人头癣：临床特征与治疗反应
Mycoses. 2023 Feb;66(2):144-149. doi: 10.1111/myc.13536. Epub 2022 Oct 27.
5
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.比美替尼：一种用于治疗银屑病和银屑病关节炎的双重 IL-17A 和 IL-17F 抑制剂。
Expert Rev Clin Immunol. 2021 Oct;17(10):1073-1081. doi: 10.1080/1744666X.2021.1967748. Epub 2021 Aug 20.
6
Epidemiological survey of 42 403 dermatophytosis cases examined at Nagasaki University Hospital from 1966 to 2015.1966 年至 2015 年在长崎大学医院检查的 42403 例皮肤癣菌病的流行病学调查。
J Dermatol. 2020 Jun;47(6):615-621. doi: 10.1111/1346-8138.15340. Epub 2020 Apr 15.
7
A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate.一例伴有发疹性真菌病的面癣、体癣和甲癣，经口服伏立康唑赖氨酸盐乙醇酸盐成功治疗。
Med Mycol J. 2021;62(1):1-4. doi: 10.3314/mmj.20-00015.
8
Tinea faciei in a newborn due to Trichophyton tonsurans.新生儿面部须癣毛癣菌所致的面癣。
J Biomed Res. 2013 Jan;27(1):71-4. doi: 10.7555/JBR.27.20120102. Epub 2012 Dec 19.
9
An unusual clinical presentation of tinea faciei caused by Trichophyton mentagrophytes var. erinacei.由须癣毛癣菌猬变种引起的面部癣的一种不寻常临床表现。
Pediatr Dermatol. 2011 Mar-Apr;28(2):210-2. doi: 10.1111/j.1525-1470.2011.01391.x.
10
[Clinical study of 57 cases of infection with Trichophyton tonsurans examined at a dermatology clinic in Saga Prefecture, Japan].[日本佐贺县一家皮肤科诊所对57例须癣毛癣菌感染病例的临床研究]
Nihon Ishinkin Gakkai Zasshi. 2007;48(2):79-84. doi: 10.3314/jjmm.48.79.

引用本文的文献

1
Severe tinea faciei mimicking favus-like lesions linked to rabbit exposure: A case report.酷似黄癣样损害的严重面部癣，与接触兔子有关：一例报告。
J Int Med Res. 2025 Jun;53(6):3000605251345893. doi: 10.1177/03000605251345893. Epub 2025 Jun 5.
2
[Onychomycosis in children and adolescents-case report and overview of the literature].[儿童和青少年甲癣——病例报告及文献综述]
Dermatologie (Heidelb). 2025 May;76(5):301-312. doi: 10.1007/s00105-025-05502-3. Epub 2025 Apr 9.

本文引用的文献

1
Evaluating bimekizumab safety.评估比美吉珠单抗的安全性。
Br J Dermatol. 2024 Mar 15;190(4):458-459. doi: 10.1093/bjd/ljad451.
2
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.布罗达单抗治疗中重度斑块状银屑病的安全性：来自随机III期试验长达3年治疗的汇总数据
Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429.
3
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).
比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
4
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.比美吉珠单抗治疗中度至重度斑块状银屑病的疗效和安全性：随机 BE RADIANT 3b 期试验开放性扩展的两年间结果。
J Am Acad Dermatol. 2023 Sep;89(3):486-495. doi: 10.1016/j.jaad.2023.04.063. Epub 2023 May 12.
5
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).在未接受过生物治疗的银屑病关节炎患者中使用比美吉珠单抗：一项随机、双盲、安慰剂对照的3期试验（BE OPTIMAL）。
Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6.
6
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
7
Successful Management of Psoriasis and Treatment-induced Tinea Incognito: A Case Report.银屑病及治疗诱发的隐匿性癣的成功管理：一例报告
J Clin Aesthet Dermatol. 2020 Sep;13(9 Suppl 1):S21-S25. Epub 2020 Sep 1.
8
Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections.维生素 A 血清浓度在接受 IL-17 抑制剂治疗的银屑病患者中预防皮肤和全身真菌感染的预测作用。
J Pharmacol Sci. 2020 Sep;144(1):52-56. doi: 10.1016/j.jphs.2020.06.003. Epub 2020 Jun 11.
9
Molecular diagnosis of kerion celsi caused by in a Italian child.一名意大利儿童中由[具体病因未给出]引起的蜂窝状脓肿的分子诊断
Med Mycol Case Rep. 2019 Apr 27;24:72-74. doi: 10.1016/j.mmcr.2019.04.010. eCollection 2019 Jun.
10
Interleukin-17 in Antifungal Immunity.抗真菌免疫中的白细胞介素-17
Pathogens. 2019 Apr 22;8(2):54. doi: 10.3390/pathogens8020054.